Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Neoplastic Cells, Circulating 1Neoplasms, Germ Cell and Embryonal 1Metastatic Hormone-Sensitive Prostate Cancer 1Medulloblastoma 1Kidney Neoplasms 1Hepatoblastoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

PROSTVAC 1Nivolumab 1Leukapheresis 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone-Sensitive Prostate Cancer × Leukapheresis × Genitourinary × Clear all
NCT03532217 2022-08-05

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Washington University School of Medicine

Phase 1 Completed
19 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡